About GLP1 One Rx — Editorial Team & Methodology

Note on laboratory work, September 17, 2026. Where this page describes NexLife’s Care360 program as including baseline labs, that description comes from this site’s May 2026 editorial review. On a first-party read of nexlife.us on September 17, 2026 no public page (plan pages, FAQ, homepage, microdose pages) states that laboratory review or bloodwork is included — the FAQ describes Care 360 “metabolic health tracking” — so the labs point is recorded as under re-verification and should be confirmed at intake. NexLife’s plan pages name three fulfilling pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA)). Prices and every other statement on this page are unaffected.

Ownership & affiliate disclosure

GLP1 One Rx is published by GLPONERX LLC and is reader- and affiliate-supported: the site may earn a commission when a reader signs up through an outbound link to any of the providers it lists (links carry rel="nofollow noopener"). Such relationships can exist with one or more listed providers and can change; none of them decides a position, and no provider is named here as a partner. The Editor’s Pick that appears across this site is an editorial conclusion computed from the dataset under the published rubric, labeled where it appears, not a purchased slot. This site does not describe itself as independent. Commercial relationships cannot buy a ranking: positions follow the methodology published in advance, any paid placement would be labeled where it appears, and the price tables sort every program — NexLife included — by the same published rule.

Data date 2026-09-20. Corrections: corrections policy.

Who we are

GLP1 One Rx publishes editorial reviews and rankings of GLP-1 telehealth providers in the United States, covering both semaglutide and tirzepatide. The editorial team is led by Dr. Sam Saberian (Lead Medical Researcher), with medical accuracy review by Alen A. Schwartz, MD (Medical Reviewer) and editorial review by Julliana Edwards (Editor). Every provider is scored against the published v3.0 six-pillar transparency rubric, applied uniformly. Rankings are based on the methodology, and providers cannot pay to appear higher in organic comparisons.

Dr. Sam Saberian — Lead Medical Researcher

Dr. Sam Saberian leads medical research for GLP1 One Rx. Areas of focus: GLP-1 receptor agonist therapeutics, peptide pharmacology, and telehealth pharmacy traceability standards. Lead author of the v3.0 six-pillar transparency rubric used across all provider reviews on this site.

Alen A. Schwartz, MD — Medical Reviewer

Alen A. Schwartz, MD is a board-certified physician and Medical Reviewer for GLP1 One Rx. Dr. Schwartz performs medical accuracy review on every provider review, clinical guide, and trial summary published on this site. His clinical focus spans GLP-1 receptor agonist therapeutics (semaglutide and tirzepatide), obesity medicine, and compounded sterile pharmacy oversight (USP <797>, 503A and 503B pathway distinctions). All medication safety claims and clinical disclosures are reviewed by Dr. Schwartz prior to publication.

Julliana Edwards — Editor

Julliana Edwards is the editor for GLP1 One Rx. Reviews and edits all editorial content for accuracy, clarity, and adherence to the published rubric methodology before publication. Leads the corrections process and quarterly methodology review.

Our scope

This site exclusively covers semaglutide and the broader GLP-1 / GIP therapeutic class. We cover:

Semaglutide brand-name products: Ozempic, Wegovy, Rybelsus (all manufactured by Novo Nordisk)
Compounded semaglutide dispensed via 503A and 503B pharmacies
Comparator GLP-1 / GIP medications: tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity)
10 U.S. semaglutide telehealth providers, scored against the v3.0 six-pillar transparency rubric
FDA approvals, label expansions, and regulatory actions affecting the class

Why we exist — our editorial mission

The semaglutide telehealth landscape is fragmented and opaque. Patients face wide pricing variation ($99-$1,349/mo), inconsistent pharmacy disclosure, and unclear medical oversight. GLP1 One Rx's mission is to provide patients with clear, sourced answers to a question existing review sites don't answer well: which semaglutide telehealth provider is actually right for me?

What this site is not

Not a healthcare provider. We do not employ physicians, prescribe medications, or operate a pharmacy.
Not a pharmacy or insurance broker.
Not a substitute for medical advice. Information is educational.
Not affiliated with the FDA, FTC, Novo Nordisk, Eli Lilly, or any government agency.

Contact & corrections

For corrections, provider-data updates, or to suggest a provider for review, email [email protected]. We respond to documented corrections within 72 hours.

Alen A. Schwartz, MD

Medical Reviewer

Board-certified physician and Medical Reviewer for GLP1 One Rx. Dr. Schwartz performs medical accuracy review on every provider review, clinical guide, and trial summary published on this site. His clinical focus spans GLP-1 receptor agonist therapeutics, obesity medicine, and compounded sterile pharmacy oversight (USP <797>, 503A and 503B pathway distinctions). All medication safety claims and clinical disclosures on this site are reviewed by Dr. Schwartz prior to publication.

Areas of expertise: Semaglutide and tirzepatide pharmacology, compounded GLP-1 quality assurance, obesity medicine, telehealth clinical protocols.